View Older Stories View More Recent Stories
-
BofA sees attractive growth in this large-cap pharma stock
-
Morgan Stanley Upgrades Sanofi (SNY) to Overweight
-
Analysts postive on Nektar opportunity after Sanofi data
-
William Blair on Sanofi (SNY): 'We believe it will be important to see the efficacy broken out by prior advanced therapy'
-
Regeneron (REGN) Shares Decline on the Open
-
BofA Securities Reiterates Buy Rating on Sanofi (SAN:FP) (SNY)
-
Jefferies Reiterates Buy Rating on Sanofi (SAN:FP) (SNY)
-
Leerink Partners Reiterates Outperform Rating on Sanofi (SNY)
-
Sanofi reports results from atopic dermatitis trial of amlitelimab
-
Deutsche Bank Upgrades Sanofi (SAN:FP) (SNY) to Buy
-
Here's how Sanofi (SNY) NPV could move on upcoming Phase 3 readouts
-
Sanofi (SNY) halts Praluent supply in China due to limited availability
-
JPMorgan Upgrades Sanofi (SAN:FP) (SNY) to Overweight
-
Increasing unusual call option volume: CWAN PRMB UNIT SNY PGEN HLF NB VRNT FE HESM
-
Sanofi (SNY) Reports Q2 EPS of EUR1.59; offers guidance
-
Thermo Fisher to acquire Sanofi's New Jersey manufacturing site
-
Adagene (ADAG) announces up to $25 million strategic investment from Sanofi (SNY)
-
Kymera Therapeutics (KYMR) PT Lowered to $64 at Jefferies
-
Sanofi (SAN:FP) (SNY) PT Lowered to EUR8.40 at BofA Securities
-
Sanofi (SNY) Prices EUR 1.5B in Notes Offerings
-
Bernstein: 'Why Are We Bullish on Sanofi (SAN:FP) (SNY) ?'
-
Stifel Reiterates Buy Rating on Nurix (NRIX)
-
Leerink Partners Reiterates Market Perform Rating on Nurix (NRIX)
-
Citi Reiterates Sell Rating on Blueprint Medicines (BPMC) As Co is Acquired
-
Sanofi (SNY) Exercises License Extension Option to Nurix’s (NRIX) STAT6 Program
-
Sanofi to acquire Blueprint Medicines, $129 per share
-
Jefferies: These 3 catalysts could drive upside in Sanofi shares
-
TD Cowen Reiterates Hold Rating on Sanofi (SNY)
-
Sanofi (SNY) opens $130 million NJ offices
-
Jefferies Downgrades Vigil Neuroscience Inc (VIGL) to Hold
-
Sanofi (SNY) to acquire Vigil Neuroscience
-
Sanofi (SNY) announces plans to invest $20 billion in the U.S. through 2030
-
HSBC cuts biotech stocks: Eli Lilly lowered to Reduce
-
Sanofi (SNY) Tops Q1 EPS by 12c; reaffirms guidance
-
Sanofi Q1 earnings preview: analysts focus on pipeline, US policy risks
-
BNP Paribas Exane Starts Sanofi (SAN:FP) (SNY) at Outperform
-
Pharma stocks slide after Trump signals tariffs on sector
-
FDA approves Sanofi’s (SNY) hemophilia treatment Qfitlia
-
Regeneron (REGN, Sanofi (SNY): Dupixent Approved as the First-ever Biologic Medicine in Japan for Patients with COPD
-
Goldman Sachs Starts Sanofi (SNY) at Neutral
-
Goldman Sachs Starts Sanofi (SAN:FP) (SNY) at Neutral
-
Sanofi (SNY) adopts FDA-selected flu strains to ensure readiness for the 2025-26 flu season
-
Expect the beat-and-raise path to continue for this European pharma name
-
Sanofi's Rilzabrutinib gets orphan designation by FDA for AIHA treatment
-
Sanofi (SAN:FP) (SNY) PT Raised to EUR6.50 at CFRA
-
Deutsche Bank Upgrades Sanofi (SAN:FP) (SNY) to Hold
-
Sanofi (SAN:FP) (SNY) PT Raised to EUR120 at Leerink Partners
-
Sanofi (SNY) Tops Q4 EPS by 53c; offers outlook
-
Sanofi (SNY 1700 contracts of February 50 puts trade
-
TD Cowen on Pharma: '10 Events in 2025 That Could Change Practice, Alter Companies, Move Stocks'
